Ernexa Therapeutics Inc. (ERNA) Gains from Investment Securities (2011 - 2025)

Ernexa Therapeutics (ERNA) has 7 years of Gains from Investment Securities data on file, last reported at -$1000.0 in Q1 2025.

• Quarterly Gains from Investment Securities fell 101.43% year-over-year to -$1000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$1000.0 (up 99.89% YoY) and the FY2025 annual result came in at -$1000.0, down 101.52% from the prior year.
• Gains from Investment Securities rose to -$1000.0 in Q1 2025, from -$831000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $570000.0 in Q4 2021 to a low of -$1.0 million in Q3 2022.
• A 5-year average of -$201384.6 and a median of -$49000.0 in 2023 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 98.04% — and 2024, when it slumped 4055.0%.
• Tracing ERNA's Gains from Investment Securities over 5 years: stood at $570000.0 in 2021, then slumped by 152.98% to -$302000.0 in 2022, then jumped by 83.77% to -$49000.0 in 2023, then slumped by 1595.92% to -$831000.0 in 2024, then jumped by 99.88% to -$1000.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$1000.0 (Q1 2025), -$831000.0 (Q3 2024), and -$136000.0 (Q2 2024), per Business Quant data.